Home > Keywords > Thématique > Partenariat

Partenariat

Articles

  • Vect-Horus, AAA form scientific collaboration to open new avenues in treatment of brain diseases
    28 January 2019, by Jonathan NOWAK

    The partnership will develop new molecules for the treatment of brain diseases
    Vect-Horus, a French company specialized in the development of vector molecules for the central nervous system, announces today it has signed a scientific collaboration agreement with Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM). The financial terms of the deal have not been disclosed.
    This agreement is part of Vect-Horus’ strategy to leverage (…)

  • Relocation of the company to support its development
    1 October 2019, by Elodie DORMES

    Relocation of Vect-Horus in medical faculty of the La Timone campus to maintain strong collaborative working environment with its historical partners and support its development.

  • Signature of a Research Common Lab with the Institute for NeuroPhysiopathology (UMR7051 CNRS-AMU)
    28 January 2019, by Jonathan NOWAK

    Since its incorporation in 2005 VECT-HORUS is a leading partner of the French academic institutions CNRS and Aix-Marseille University. Indeed, the company as a spin-off of the NICN (UMR7259 CNRS-AMU) now Institute for NeuroPhysiopathology INP (UMR7051 CNRS-AMU) directed by Dr. Michel KHRESTCHATISKY, cofounder of the company, develops inventions and technologies derived from the “BBB and Neuroinflammation Team”. VECT-HORUS has established a long-term highly efficient collaboration with this (…)

  • Vect-Horus and Cerimed announce collaboration to support the development of its theragnostic agents
    17 November 2020, by Elodie DORMES

    Vect-Horus is co-developing with Radiomedix one agent which will enter clinical trials in 2021 for the diagnosis of glioblastoma.
    With Cerimed, Vect-Horus also pursues the investigations on its other theragnostic candidates targeting the Low-Density Lipoprotein Receptor, which has been shown to be expressed at high levels in some tumours, including pancreatic tumours.

  • Vect-Horus announces agreement with Johnson&Johnson Innovation
    18 January 2019, by Jonathan NOWAK

    Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

  • Vect-Horus further strengthens leadership with appointment of strategy and finance executive Jérôme Berger to its Board of Directors
    3 February 2025, by Emmanuelle BETTENDORF

    We are excited that Jerome Berger is joining our Board of Directors!
    Jerome brings vast expertise in strategy, finance, and venture capital in the technology and life sciences sectors, which will be invaluable as Vect-Horus accelerates its growth and development.
    “Jerome’s unparalleled experience in strategy, venture capital and global financing, coupled with his strong background in digital health and life sciences, will be invaluable in supporting the development of Vect-Horus as we (…)

  • Vect-Horus is a partner laureate of the ANR MALZ 2010 call for proposals
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) MALZ 2010 call for proposals and will be involved in the ADHOC project coordinated by the UMR7259 laboratory (Coordinator, Pr. François Féron).
    This project received support (label) from the EUROBIOMED Biocluster.

  • Vect-Horus is a partner laureate of the ANR MALZ 2011 call for proposals
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) MALZ 2011 call for proposals and will be involved in the PREVENTAD project coordinated by the UMR7259 laboratory (Coordinator, Dr. Michel Khrestchatisky).
    This project received support (label) from the EUROBIOMED Biocluster.
    VECT-HORUS recruits to reinforce its in vitro BBB model platform.

  • Vect-Horus announces the signing of a scientific collaboration agreement with SANOFI in the field of neurodegenerative diseases
    28 January 2019, by Jonathan NOWAK

    The goal of this collaboration is to use VECT-HORUS’ proprietary technology to transport therapeutic antibodies into the brain for the treatment of a neurodegenerative disease.

  • Vect-Horus is a partner laureate of the ANR RPIB Call 2013 for proposals
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) RPIB Call 2013 for proposals and will be involved in the VEC2Brain project involving 3 academic laboratories. The project will be coordinated by Dr Michel Khrestchatisky, Director of the UMR7259 laboratory (CNRS and Aix-Marseille University) and involves the U705 laboratory (Director, Pr. Jean-Michel Scherrmann) of INSERM and the SIMOPRO laboratory (Director Dr. Vincent Dive) of the CEA. This project received (…)